Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P Rossiter

Showing results (31-40 of 31) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 31 results.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Pageof 4

Showing results (31-40 of 31) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 31 results.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Pageof 4